New Delhi, May 8 -- New biosimilar launches and scaling up of recently launched products are expected to drive growth for Biocon in FY27, as the company pivots from a heavy investment phase towards improving capacity utilization, profitability and margins across its biopharmaceutical businesses, managing director and chief executive Shreehas Tambe told reporters on Friday.

Biocon posted its financial results for the fourth quarter and the full year FY26 late on Thursday.

"We successfully integrated our biosimilars and generics business to create one biopharmaceutical enterprise with greater scale capability and reach.the focus now shifts towards improving utilization of the capacity we've built, expanding margins and driving a steady im...